107 related articles for article (PubMed ID: 19451089)
1. Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.
Fatima N; Chelius D; Luke BT; Yi M; Zhang T; Stauffer S; Stephens R; Lynch P; Miller K; Guszczynski T; Boring D; Greenwald P; Ali IU
Cancer Genomics Proteomics; 2009; 6(1):41-9. PubMed ID: 19451089
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.
Lou J; Fatima N; Xiao Z; Stauffer S; Smythers G; Greenwald P; Ali IU
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1598-606. PubMed ID: 16985019
[TBL] [Abstract][Full Text] [Related]
3. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
5. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
6. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
7. A proteomics approach to identify changes in protein profiles in serum of Familial Adenomatous Polyposis patients.
Quaresima B; Crugliano T; Gaspari M; Faniello MC; Cosimo P; Valanzano R; Genuardi M; Cannataro M; Veltri P; Baudi F; Doldo P; Cuda G; Venuta S; Costanzo F
Cancer Lett; 2008 Dec; 272(1):40-52. PubMed ID: 18667268
[TBL] [Abstract][Full Text] [Related]
8. [Application of serum protein markers to distinguish familial adenomatous polyposis (FAP) and sporadic colorectal adenomas].
Cai SR; Yu JK; Jiang WZ; Zhang SZ; Zheng S
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):192-5. PubMed ID: 19615258
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
[TBL] [Abstract][Full Text] [Related]
10. Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib.
Fatima N; Yi M; Ajaz S; Stephens RM; Stauffer S; Greenwald P; Munroe DJ; Ali IU
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3051-61. PubMed ID: 18957522
[TBL] [Abstract][Full Text] [Related]
11. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.
Xiao Z; Luke BT; Izmirlian G; Umar A; Lynch PM; Phillips RK; Patterson S; Conrads TP; Veenstra TD; Greenwald P; Hawk ET; Ali IU
Cancer Res; 2004 Apr; 64(8):2904-9. PubMed ID: 15087410
[TBL] [Abstract][Full Text] [Related]
12. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Chu AJ; Chou TH; Chen BD
Front Biosci; 2004 Sep; 9():2697-713. PubMed ID: 15353307
[TBL] [Abstract][Full Text] [Related]
13. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
17. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
20. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
